Multiple mechanisms of dimethyl fumarate in amyloid β-induced neurotoxicity in human neuronal cells

Journal of Cellular and Molecular Medicine

Volumn 22, Issue 2, 2018, Pages 1081-1094

  Campolo, Michela ^a   Casili, Giovanna ^a   Lanza, Marika ^a   Filippone, Alessia ^a   Paterniti, Irene ^a   Cuzzocrea, Salvatore ^a,b   Esposito, Emanuela ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; dimethyl fumarate; Nf kB; Nrf2; oxidative stress; tau hyper phosphorylation

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; GLUTATHIONE DISULFIDE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; SMALL INTERFERING RNA; TAU PROTEIN; TRANSCRIPTION FACTOR NRF2; AMYLOID BETA PROTEIN; ANTIOXIDANT; NEUROPROTECTIVE AGENT; NEUROTOXIN; NFE2L2 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ARTICLE; BONE MARROW BIOPSY; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; EX VIVO STUDY; HIPPOCAMPAL SLICE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LIPID PEROXIDATION; NERVE CELL; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SH-SY5Y CELL LINE; SK-N-SH CELL LINE; ANIMAL; CELL SURVIVAL; DRUG EFFECT; HIPPOCAMPUS; METABOLISM; MOUSE; NEUROPROTECTION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; CELL SURVIVAL; DIMETHYL FUMARATE; HIPPOCAMPUS; HUMANS; INFLAMMATION; MICE; NEURONS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NF-E2-RELATED FACTOR 2; NF-KAPPA B; OXIDATIVE STRESS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TAU PROTEINS;

EID: 85041003818     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.13358     Document Type: Article

References (79)

1. Anna P, Federico S, Massimo V. Resilience to Alzheimer's disease: the role of physical activity. Curr Alzheimer Res. 2017 [Epub ahead of print].
2. Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013; 80: 1778–83.
3. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7: 137–52.
4. Mayo CD, Mazerolle EL, Ritchie L, et al. Longitudinal changes in microstructural white matter metrics in Alzheimer's disease. Neuroimage Clin. 2016; 13: 330–8.
5. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002; 298: 789–91.
6. Ardestani PM, Evans AK, Yi B, et al. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist. Neuropharmacology. 2017; 116: 371–386.
7. Decker M, Munoz-Torrero D. Special issue: “molecules against alzheimer”. Molecules. 2016; 21: 12.
8. Rygiel K. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol. 2016; 48: 629–36.
9. Di Bona D, Scapagnini G, Candore G, et al. Immune-inflammatory responses and oxidative stress in Alzheimer's disease: therapeutic implications. Curr Pharm Des. 2010; 16: 684–91.
10. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des. 2010; 16: 2766–78.
11. Perry G, Cash AD, Smith MA. Alzheimer Disease and Oxidative Stress. J Biomed Biotechnol. 2002; 2: 120–3.
12. Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013; 5(1): 6.
13. Albrecht P, Bouchachia I, Goebels N, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012; 9: 163.
14. Werdenberg D, Joshi R, Wolffram S, et al. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos. 2003; 24: 259–73.
15. Litjens NH, Burggraaf J, van Strijen E, et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004; 58: 429–32.
16. Bomprezzi R. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord. 2015; 8: 20–30.
17. Fox RJ, Kita M, Cohan SL, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014; 30: 251–62.
18. Chen XL, Dodd G, Thomas S, et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol. 2006; 290: H1862–70.
19. Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006; 145: 101–7.
20. Ganesh Yerra V, Negi G, Sharma SS, et al. Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-kappaB pathways in diabetic neuropathy. Redox Biol. 2013; 1: 394–7.
21. Kosenko EA, Solomadin IN, Tikhonova LA, et al. Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid-beta peptides, systemic ammonia and erythrocyte energy metabolism. CNS Neurol Disord Drug Targets. 2013; 13: 112–9.
22. Williams TI, Lynn BC, Markesbery WR, et al. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging. 2006; 27: 1094–9.
23. Persson T, Popescu BO, Cedazo-Minguez A. Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail? Oxid Med Cell Longev. 2014; 2014: 427318.
24. Feng Y, Wang X. Antioxidant therapies for Alzheimer's disease. Oxid Med Cell Longev. 2012; 2012: 472932.
25. Zhao Y, Bhattacharjee S, Jones BM, et al. Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer's disease (AD) and in primary human neuronal-glial (HNG) cells. Mol Neurobiol. 2014; 50: 97–106.
26. Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 2001; 107: 247–54.
27. Boissiere F, Hunot S, Faucheux B, et al. Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer's disease. NeuroReport. 1997; 8: 2849–52.
28. Wardyn JD, Ponsford AH, Sanderson CM. Dissecting molecular cross-talk between Nrf2 and NF-kappaB response pathways. Biochem Soc Trans. 2015; 43: 621–6.
29. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 1973; 33: 2643–52.
30. Paterniti I, Cordaro M, Campolo M, et al. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation. CNS Neurol Disord Drug Targets. 2012; 13: 1530–41.
31. Campolo M, Casili G, Biundo F, et al. The neuroprotective effect of dimethyl fumarate in a MPTP-mouse model of Parkinson's disease: involvement of reactive oxygen species/nuclear factor-kappaB/nuclear transcription factor related to NF-E2. Antioxid Redox Signal. 2016; [Epub ahead of print].
32. Bhatia R, Lin H, Lal R. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB J. 2000; 14: 1233–43.
33. Pellegrini-Giampietro DE, Cozzi A, Peruginelli F, et al. 1-Aminoindan-1,5-dicarboxylic acid and (S)-(+)-2-(3’-carboxybicyclo[1.1.1] pentyl)-glycine, two mGlu1 receptor-preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischaemia. Eur J Neurosci. 1999; 11: 3637–47.
34. Scuderi C, Valenza M, Stecca C, et al. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-alpha. J Neuroinflammation. 2012; 9: 49.
35. Paterniti I, Cordaro M, Campolo M, et al. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation. CNS Neurol Disord Drug Targets. 2014; 13: 1530–41.
36. Lin-Holderer J, Li L, Gruneberg D, et al. Fumaric acid esters promote neuronal survival upon ischemic stress through activation of the Nrf2 but not HIF-1 signaling pathway. Neuropharmacology. 2016; 105: 228–40.
37. Esposito E, Iacono A, Muia C, et al. Signal transduction pathways involved in protective effects of melatonin in C6 glioma cells. J Pineal Res. 2008; 44: 78–87.
38. Olivieri G, Brack C, Muller-Spahn F, et al. Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochem. 2000; 74: 231–6.
39. Campolo M, Casili G, Biundo F, et al. The neuroprotective effect of dimethyl fumarate in a MPTP-mouse model of Parkinson's disease: involvement of reactive oxygen species/nuclear factor-kappaB/nuclear transcription factor related to NF-E2. Antioxid Redox Signal. Epub head of print.
40. Lee KW, Im JY, Woo JM, et al. Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease. Neurotherapeutics. 2013; 10: 143–53.
41. Meng X, Wang M, Sun G, et al. Attenuation of Abeta25-35-induced parallel autophagic and apoptotic cell death by gypenoside XVII through the estrogen receptor-dependent activation of Nrf2/ARE pathways. Toxicol Appl Pharmacol. 2014; 279: 63–75.
42. Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med. 1999; 340: 1970–80.
43. Wang Y, Veremeyko T, Wong AH, et al. Downregulation of miR-132/212 impairs S-nitrosylation balance and induces tau phosphorylation in Alzheimer's disease. Neurobiol Aging. 2017; 51: 156–166.
44. Zheng H, Fridkin M, Youdim M. New approaches to treating Alzheimer's disease. Perspect Medicin Chem. 2015; 7: 1–8.
45. Liu Y, Qiu J, Wang Z, et al. Dimethylfumarate alleviates early brain injury and secondary cognitive deficits after experimental subarachnoid hemorrhage via activation of Keap1-Nrf2-ARE system. J Neurosurg. 2015; 123: 915–23.
46. Zhang N, Shu HY, Huang T, et al. Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS One. 2014; 9: e100286.
47. Owen JB, Butterfield DA. Measurement of oxidized/reduced glutathione ratio. Methods Mol Biol. 2010; 648: 269–77.
48. Yao Y, Miao W, Liu Z, et al. Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice. Transl Stroke Res. 2016; 7: 535–47.
49. Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol. 2008; 4: 278–86.
50. Thummayot S, Tocharus C, Pinkaew D, et al. Neuroprotective effect of purple rice extract and its constituent against amyloid beta-induced neuronal cell death in SK-N-SH cells. Neurotoxicology. 2014; 45: 149–58.
51. Pinkaew D, Changtam C, Tocharus C, et al. Di-O-demethylcurcumin protects SK-N-SH cells against mitochondrial and endoplasmic reticulum-mediated apoptotic cell death induced by Abeta25-35. Neurochem Int. 2015; 80: 110–9.
52. Butterfield DA, Drake J, Pocernich C, et al. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med. 2001; 7: 548–54.
53. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med. 1997; 23: 134–47.
54. Schipper HM, Bennett DA, Liberman A, et al. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging. 2006; 27: 252–61.
55. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci. 2005; 233: 3–13.
56. Raina AK, Templeton DJ, Deak JC, et al. Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease. Redox Rep. 1999; 4: 23–7.
57. Wang Y, Santa-Cruz K, DeCarli C, et al. NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Alzheimer's disease. Neurobiol Aging. 2000; 21: 525–31.
58. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012; 2: a006346.
59. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367: 1098–107.
60. Rostami Yazdi M, Mrowietz U. Fumaric acid esters. Clin Dermatol. 2008; 26: 522–6.
61. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012; 341: 274–84.
62. Jing X, Shi H, Zhang C, et al. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity. Neuroscience. 2014; 286: 131–40.
63. Klyubin I, Cullen WK, Hu NW, et al. Alzheimer's disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain. 2012; 5: 25.
64. Sehlin D, Englund H, Simu B, et al. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012; 7: e32014.
65. Whalen BM, Selkoe DJ, Hartley DM. Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration. Neurobiol Dis. 2005; 20: 254–66.
66. Li S, Jin M, Koeglsperger T, et al. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011; 31: 6627–38.
67. Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007; 27: 796–807.
68. Shtifman A, Ward CW, Laver DR, et al. Amyloid-beta protein impairs Ca2 + release and contractility in skeletal muscle. Neurobiol Aging. 2010; 31: 2080–90.
69. Jazwa A, Rojo AI, Innamorato NG, et al. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal. 2011; 14: 2347–60.
70. Kaidery NA, Banerjee R, Yang L, et al. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal. 2013; 18: 139–57.
71. Chao XJ, Chen ZW, Liu AM, et al. Effect of tacrine-3-caffeic acid, a novel multifunctional anti-Alzheimer's dimer, against oxidative-stress-induced cell death in HT22 hippocampal neurons: involvement of Nrf2/HO-1 pathway. CNS Neurosci Ther. 2014; 20: 840–50.
72. Masci A, Mattioli R, Costantino P, et al. Neuroprotective Effect of Brassica oleracea Sprouts Crude Juice in a Cellular Model of Alzheimer's Disease. Oxid Med Cell Longev. 2015; 2015: xidative Medicine and Cellular Longevity, vol. 2015, Article ID 781938, 17 pages, 2015. doi:10.1155/2015/781938.
73. Petri S, Korner S, Kiaei M. Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS. Neurology Research International, vol. 2012, Article ID 878030, 7 pages, 2012. doi:10.1155/2012/878030.
74. Huang Y, Li W, Su ZY, et al. The complexity of the Nrf2 pathway: beyond the antioxidant response. J Nutr Biochem. 2015; 26: 1401–13.
75. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007; 47: 89–116.
76. Liu H, Wang H, Shenvi S, et al. Glutathione metabolism during aging and in Alzheimer disease. Ann N Y Acad Sci. 2004; 1019: 346–9.
77. Butterfield DA, Castegna A, Lauderback CM, et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging. 2002; 23: 655–64.
78. Nair S, Doh ST, Chan JY, et al. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer. 2008; 99: 2070–82.
79. Agholme L, Lindstrom T, Kagedal K, et al. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis. 2010; 20: 1069–82.